- Home
- WK vs EWTX Comparison
WK vs EWTX Comparison
Compare WK & EWTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | WK | EWTX |
|---|---|---|
| Founded | 2008 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.9B | 4.3B |
| IPO Year | 2014 | 2021 |
Fundamental Metrics
Financial Performance| Metric | WK | EWTX |
|---|---|---|
| Price | $69.33 | $39.53 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 11 | 13 |
| Target Price | ★ $89.80 | $52.62 |
| AVG Volume (30 Days) | 884.7K | ★ 1.4M |
| Earning Date | 11-04-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 52.53 | N/A |
| EPS | ★ 0.58 | N/A |
| Revenue | ★ $884,568,000.00 | N/A |
| Revenue This Year | $17.81 | N/A |
| Revenue Next Year | $15.45 | N/A |
| P/E Ratio | $124.31 | ★ N/A |
| Revenue Growth | ★ 19.75 | N/A |
| 52 Week Low | $43.34 | $14.25 |
| 52 Week High | $97.10 | $48.51 |
Technical Indicators
Market Signals| Indicator | WK | EWTX |
|---|---|---|
| Relative Strength Index (RSI) | 47.34 | 40.50 |
| Support Level | $50.58 | $37.50 |
| Resistance Level | $76.45 | $41.04 |
| Average True Range (ATR) | 3.15 | 2.15 |
| MACD | -0.47 | -0.39 |
| Stochastic Oscillator | 40.79 | 12.75 |
Price Performance
Historical ComparisonAbout WK Workiva Inc.
Workiva Inc is an AI-powered platform for trust, transparency, and accountability. Accounting, finance, sustainability, risk, and audit teams rely on Workiva for their mission-critical work. It transforms how customers connect data, unify processes, and empower teams in a secure, AI-powered, audit-ready, collaborative platform. Company's Geographical region consist of USA, Netherland, UK, and Others. Majority of revenue is from USA.
About EWTX Edgewise Therapeutics Inc.
Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is developing novel therapeutics for muscular dystrophies and serious cardiac conditions. The company's product candidates are Sevasemten, EDG-7500, EDG-003, and EDG-15400. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies, including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company's products are currently in different stages of their development, being developed to target key muscle proteins and modulators to address a broad array of muscle diseases.